About Acino
Acino is a company based in Zurich (Switzerland) founded in 1836 was acquired by ADQ in September 2021. It operates as a Direct-to-Consumer (D2C), Reseller / Distribution, and Licensing Model. Acino has completed 1 acquisition, including M8 Pharmaceuticals. Acino offers products and services including Innovative Medicines, Generic Medicines, and Manufacturing Services.
- Headquarter Zurich, Switzerland
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Acino International Ag
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
ADQ
& 2 more
-
Employee Count
Not available
- Investments & Acquisitions
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Acino
Acino offers a comprehensive portfolio of products and services, including Innovative Medicines, Generic Medicines, and Manufacturing Services.
Innovative medicines are developed for various health conditions.
Generic medicines are distributed to improve healthcare access.
Manufacturing services are provided for pharmaceutical product development.
People of Acino
Unlock access to complete
Human Resources and Administration
15 people
Finance and Accounting
11 people
Head Team
10 people
Software Development Team
9 people
Global Team
6 people
Sales and Marketing
5 people
Legal and Compliance
5 people
Leadership Team
3 people
Unlock access to complete
Funding Insights of Acino
Detailed funding history for Acino
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Acino
Acino has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include ADQ, Nordic Capital and Avista Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
ADQ is recognized as a leading sovereign investor focused on sustainable economic transformation in Abu Dhabi.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Private equity investments are focused on the United States market.
|
Locked | Locked | Locked |
Investor details for Acino
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Acino
Acino has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include M8 Pharmaceuticals.
Investment portfolio details for Acino
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Pharmaceutical company develop and commercialize leading original medicines
|
Locked | Locked | 2007 | Locked |
Complete acquisition details for Acino
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Acino
Detailed financials for Acino
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Acino Comparisons
Peer comparison for Acino
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Acino
Detailed competitors of Acino
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Acino
Complete news archive for Acino
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Acino
Acino was founded in 1836.
Acino is headquartered in Zurich, Switzerland.
Steffen Saltofte is the current CEO of Acino.
Acino is involved in the development, manufacturing, and marketing of innovative and generic medicines across various therapeutic areas. Operations are conducted in regions including Africa, Latin America, the Middle East, Türkiye, North Africa, Ukraine, and Eurasian countries. Advanced drug delivery systems are produced, focusing on dispersible and complex modified release formulations. Partnerships are established with global pharma companies for in-licensing and out-licensing of products. A commitment to sustainability and health matters is maintained through educational initiatives on conditions like hypertension and infectious diseases.
Acino offers Innovative Medicines, Generic Medicines, and Manufacturing Services.
Acino has made 1 acquisition, including M8 Pharmaceuticals.
Acino has 3 investors. Key investors include ADQ, Nordic Capital, and Avista Capital Partners.